Patricia Louis is a content editor and social media strategist with a strong background in journalism, public relations and business. As the organic social media editor, she oversees and develops ...

The Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly’s ‌weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The FDA has clarified its policies regarding GLP-1s, stating that pharmacies must stop compounding GLP-1 drugs once branded versions are removed from the agency’s shortage list, signaling a narrower ...

Learn about compound interest. We will look at how to determine the final value, initial value, interest rate and years needed. We will investigate problems compounded continuously, daily, weekly, ...

As GLP-1 medications grow in popularity not just for treating diabetes but also for weight loss, some people are turning to alternatives that health experts warn may carry risks. Amelia Baker, a ...

In this video series you will learn the basics of logarithmic and exponential functions. We will start off by converting between exponential and logarithmic expressions. We do this so that we can ...

Eli Lilly (LLY) has issued a public warning about potential safety risks associated with compounded tirzepatide mixed with vitamin B12. Lilly tested compounded products and found “significant levels ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. as drugmakers and the FDA alike seek to crack down on the ...

WASHINGTON, March 12 (Reuters) - Compounded weight-loss drugs that contain vitamin B12 and the ‌main ingredient in Eli Lilly's (LLY.N), opens new tab Zepbound could present health risks to consumers ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting ...